QIAGEN Collaborates with Mirati to Develop KRASG12C CDx for Non-Small Cell Lung Cancer
Shots:
- The companies collaborated to develop a tissue based KRAS Cdx test to identify patients with cancers that have a KRASG12C mutation who may benefit from treatment with adagrasib- which is an investigational small molecule inhibitor of KRASG12
- The agreement initially focuses on developing CDx for NSCLC and allows to further development of tests for Mirati’s oncology programs
- The planned CDx would be a part of QIAGEN’s therascreen KRAS testing portfolio based on real-time qualitative PCR for the QIAGEN Rotor-Gene Q MDx instrument. Earlier- the companies collaborated to develop a CDx test to support glesatinib
Ref: Businesswire | Image: Reuters
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com